<DOC>
	<DOCNO>NCT02585804</DOCNO>
	<brief_summary>Patients Focal Segmental Glomerulosclerosis ( FSGS ) constitute increase proportion total glomerulonephritis ( GN ) patient cohort North America FSGS risk factor end stage renal failure . Current non-immunological FSGS therapy include use angiotensin convert enzyme inhibitor ( ACEi ) angiotensin II receptor blocker ( ARB ) , reduce intraglomerular hypertension . Unfortunately , agent lead incomplete renal protection . The aim current study determine whether addition novel sodium glucose cotransport-2 inhibitor ( SGLT2i ) standard care lead reduce intraglomerular pressure suppression proteinuria . We hypothesize combination therapy SGLT2i drug conventional RAASi result additive renal protective effect FSGS patient . A goal examine mechanism SGLT2 inhibition measure renal hemodynamic function sodium handling . Kidney function assess FSGS patient 8 week treatment SGLT2i dapagliflozin .</brief_summary>
	<brief_title>Treating Reduce Albuminuria Normalize Hemodynamic Function Focal ScLerosis With dApagliflozin Trial Effects</brief_title>
	<detailed_description>FSGS diabetic nephropathy may common pathogenic mechanism , mediate intraglomerular hypertension , lead hyperfiltration proteinuria . Given SGLT2i corrects early hemodynamic abnormality patient diabetes , aim determine similar benefit may extend patient FSGS . Based previous experimental clinical data , hypothesize SGLT2i improve renal hemodynamic abnormality characteristic FSGS promote renal injury proteinuria .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<criteria>Male female subject diagnose FSGS ≥1 month prior inform consent eGFR≥45 ml/min/1.73m2 Age 18 year great No history diabetes Body Mass Index ( BMI ) 18.5 45.0 kg/ m2 Blood pressure ≥ 100/60 screen Stable therapy either ACEi angiotensin II receptor blocker direct renin inhibitor &gt; 1 month &gt; 1 g/day &lt; 5 g/day proteinuria unless patient candidate immunosuppressive therapy Leukocyte and/or nitrite positive urinalysis untreated ; History organ transplantation , cancer , liver disease ; Bariatric surgery gastrointestinal surgery induce chronic malabsorption within past two year ; Current treatment systemic corticosteroid , calcineurin inhibitor , immunosuppressant medication ; Blood dyscrasia disorder cause hemolysis unstable red blood cell ; Premenopausal woman nurse , pregnant , childbearing potential practising acceptable method birth control ; Participation another therapeutic trial investigational drug within 30 day prior informed consent ; Alcohol drug abuse within three month prior inform consent would interfere trial participation ongoing clinical condition would jeopardize subject safety study compliance base investigator judgement ; Liver disease , define serum level alanine transaminase , aspartate transaminase , alkaline phosphatase &gt; 3 x upper limit normal determine screening ; Cardiac , lung peripheral vascular disease stroke ; Pancreas , pancreatic islet cell renal transplant recipient ; Medical history cancer treatment cancer last five year prior screen ; History allergy angioedema RAAS inhibitor exposure ; Kidney disease due primarily another condition aside FSGS ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>FSGS , SGLT2 , chronic kidney disease , GFR , proteinuria</keyword>
</DOC>